EdgeMarket › What Octagon Capital Advisors Lp reported owning
What Octagon Capital Advisors Lp reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
903.6MPositions
29Quarter
2026-03-31Shown below
29largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics, Inc. /DE/ | 163.4M | 18.1% | 1.9M | 111.10 | +374.4% |
| COGT Cogent Biosciences, Inc. | 90.5M | 10.0% | 2.4M | 36.73 | +209.6% |
| ABVX Abivax S.A. | 75.4M | 8.3% | 677.0K | 114.95 | +59.9% |
| ALMS ALUMIS INC. | 62.4M | 6.9% | 2.8M | 24.17 | +448.1% |
| DFTX Definium Therapeutics, Inc. | 46.1M | 5.1% | 2.4M | 44.91 | +375.2% |
| AVBP ArriVent BioPharma, Inc. | 45.5M | 5.0% | 2.0M | 29.12 | +51.1% |
| TSHA Taysha Gene Therapies, Inc. | 39.6M | 4.4% | 8.9M | 6.09 | +112.2% |
| KYMR Kymera Therapeutics, Inc. | 35.4M | 3.9% | 425.0K | 119.80 | +182.9% |
| MIRM Mirum Pharmaceuticals, Inc. | 31.3M | 3.5% | 338.9K | 96.31 | +44.4% |
| BIOA BioAge Labs, Inc. | 30.6M | 3.4% | 1.7M | 9.48 | +113.5% |
| unmapped CUSIP 152309100 | 29.8M | 3.3% | 750.0K | — | — |
| unmapped CUSIP 483497103 | 29.2M | 3.2% | 1.4M | — | — |
| XENE Xenon Pharmaceuticals Inc. | 28.5M | 3.2% | 490.0K | 60.77 | +61.5% |
| unmapped CUSIP 880881107 | 27.9M | 3.1% | 530.0K | — | — |
| OCUL OCULAR THERAPEUTIX, INC | 26.8M | 3.0% | 3.2M | 11.08 | -7.4% |
| PALI PALISADE BIO, INC. | 18.0M | 2.0% | 10.3M | 2.10 | +191.7% |
| TRVI Trevi Therapeutics, Inc. | 17.7M | 2.0% | 1.5M | 17.96 | +142.0% |
| IRON Disc Medicine, Inc. | 17.3M | 1.9% | 270.0K | 79.81 | +35.9% |
| AKTS Aktis Oncology, Inc. | 17.2M | 1.9% | 960.8K | 24.07 | +19858.5% |
| CNTX Context Therapeutics Inc. | 13.8M | 1.5% | 5.2M | 0.50 | -44.7% |
| DTIL PRECISION BIOSCIENCES INC | 12.3M | 1.4% | 2.2M | 8.85 | +89.9% |
| DBVT DBV Technologies S.A. | 12.0M | 1.3% | 574.2K | 14.55 | +48.5% |
| UNCY Unicycive Therapeutics, Inc. | 6.6M | 0.7% | 1.0M | 5.63 | +37.7% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 6.4M | 0.7% | 719.0K | 9.08 | -5.7% |
| LXEO Lexeo Therapeutics, Inc. | 6.3M | 0.7% | 1.1M | 4.88 | +1.7% |
| PHVS Pharvaris N.V. | 4.7M | 0.5% | 165.0K | 36.27 | +57.7% |
| CATX Perspective Therapeutics, Inc. | 3.3M | 0.4% | 791.6K | 3.30 | -2.4% |
| EVMN Evommune, Inc. | 3.3M | 0.4% | 143.5K | 14.02 | — |
| GOSS Gossamer Bio, Inc. | 2.5M | 0.3% | 7.8M | 0.15 | -92.1% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →